Brind.

A career profile of James M. Daly detailing his appointments at Cytokinetics, Amgen, and GlaxoSmithKline.

1 report, 1 independent Updated Aug 20

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Cytokinetics Amgen GlaxoSmithKline Acadia Pharmaceuticals

Keep exploring

The entities involved

Cytokinetics
company in South San Francisco, United States
- Price targets for UDR were adjusted by Cantor Fitzgerald, Scotiabank, and Royal Bank of Canada on May 26, 2026.Sun 00:44
Amgen
American multinational biopharmaceutical company
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
GlaxoSmithKline
company in Tokyo, Japan

Nothing else this week.
Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 20GlobeNewswireCytokinetics Names Jim Daly to Board of Directors SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M.